Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Different LNP Formulations of RSV mRNA Vaccines in Healthy Adults
NCT07071558Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jul 2025
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of Sinovac RSV mRNA vaccine in respiratory syncytial virus infection (RSV) (8 arms), sponsored by Sanofi. Primary endpoints: Presence of any unsolicited systemic adverse events at 30 minutes, Presence of solicited injection site reactions at 7 days and 5 more. Started Jul 2025; status: completed.
02
Drugs
Sinovac RSV mRNA vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07071558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071558.